anti-mesothelin HiT TCR-T cell therapy SPEAR (Adaptimmune/Astellas)

N/A

Report date: 2025/01/26 19:13:15

Base Information

Drug Nameanti-mesothelin HiT TCR-T cell therapy SPEAR (Adaptimmune/Astellas)
Drug Alias NameSPEAR T-cell program (Adaptimmune/Universal Cells)TCR T-cell therapy (Adaptimmune/Astellas)allogeneic anti-mesothelin TCR T-cell therapy (Adaptimmune/Astellas)allogeneic T-cell therapy (Adaptimmune/Universal Cells)
ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionMesothelin modulators
TargetsMesothelin
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAdaptimmune Ltd
China Registration ClassN/A

Develop Information

Active CompaniesUniversal Cells IncAdaptimmune Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A